HYDRASHIFT 2/4 daratumumab removes the daratumumab interference from serum immunofixation, so the therapeutic monoclonal antibody is no longer mistaken for a residual M-protein in treated myeloma patients. 20 tests per kit, run on HYDRASYS.
Key Benefits
Unique shift technology: HYDRASHIFT daratumumab and HYDRASHIFT isatuximab avoid daratumumab or isatuximab interference on HYDRAGEL IF tests.
Trust in the results: HYDRASHIFT reduce the risk of incorrect IF interpretation to improve therapy monitoring.
Easy to implement: Fully integrated into IF protocol without sample pre-treatment for a standardized process compliant to IMWG guidelines.
Follow IMWG guidelines: Process compliant to IMWG guidelines to assess response to treatment in patient with Multiple Myeloma.
Main Characteristics
Test Principle
HYDRASHIFT is an immunofixation procedure performed on HYDRAGEL IF 2/4 gel and based on the creation of a mAb/ anti mAb immune complex shift mAb drug (daratumumab or isatuximab) in alpha zone.
This complex is visible in the IgG and kappa immunofixation tracks. A negative HYDRASHIFT result demonstrates the absence of endogenous M-protein.
Sample Type
Serum
Performances
Sensitivity
The limit of immune complex visualized is 0.3 g/L.
